AuntMinnie
APRIL 15, 2024
Total nuclear medicine patient study volumes decreased by 5.7% decrease in hospital-based studies and a 2.5% decrease in total procedures each year, with hospital-based procedures declining by 5.5% and non-hospital procedures increasing by 1.2%. and non-hospital procedures increasing by 1.2%. Of these, 5.8
AuntMinnie
MAY 8, 2024
Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer. In addition, dose calculations estimated mean dose to the arm of approximately 3 Gy.
AuntMinnie
JUNE 3, 2024
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
Future Teleradiology
NOVEMBER 21, 2023
Teleradiology & Radiology data for artificial intelligence (AI) Introduction: Nuclear medicine, a dynamic and rapidly evolving field, continues to break new ground in diagnostic and therapeutic approaches. Introduction to Nuclear Medicine: Merging Physics and Medicine: Provide an overview of nuclear medicine.
AuntMinnie
MARCH 7, 2024
In terms of 2023 spending, the average radiopharmaceutical expenditure per fixed PET site is estimated to be $517,000. In 2023, 38% of PET systems were operated by the PET department, 28% by nuclear medicine, 24% by radiology/imaging, 5% by radiation oncology, and 2% by molecular imaging.
Imaging Technology
JUNE 11, 2024
She will also raise awareness of nuclear medicine’s value to clinical colleagues and patients and will be laser-focused on breaking down barriers to radiopharmaceutical availability, reimbursement, affordability, and funding. An active SNMMI member, Jacene has been involved in many aspects of the organization.
AuntMinnie
JUNE 11, 2024
TORONTO – The radiopharmaceutical Pluvicto improves progression-free survival in patients with metastatic prostate cancer who haven’t undergone taxane therapy, according to research presented at the SNMMI meeting. Oliver Sartor, MD The study, which was awarded SNMMI’s Abstract of the Year award, shared data from the phase III PSMAfore trial.
Expert insights. Personalized for you.
111 
Let's personalize your content